ALZ.ORG/WALK JOIN · PDF file 11/7/2013 · ALZ.ORG/WALK 800.272.3900. Northern...
Embed Size (px)
Transcript of ALZ.ORG/WALK JOIN · PDF file 11/7/2013 · ALZ.ORG/WALK 800.272.3900. Northern...
northern california & northern nevada
F A L L 2013 www.alz.org
MODESTO SEPTEMBER 7 Graceada Park [email protected]
YOUNTVILLE SEPTEMBER 7 Yountville Park [email protected]
SAN FRANCISCO SEPTEMBER 21 Mission Creek Park [email protected]
YUBA CITY SEPTEMBER 21 Feather River Parkway [email protected]
FRESNO SEPTEMBER 28 Copper River Ranch Park [email protected]
SPARKS, NV SEPTEMBER 28 Sparks Marina [email protected]
APTOS OCTOBER 5 Seascape Resort and Park [email protected]
MERCED OCTOBER 5 Applegate Park [email protected]
SACRAMENTO OCTOBER 5 State Capitol [email protected]
WALNUT CREEK OCTOBER 5 Heather Farms [email protected]
CHICO OCTOBER 12 Bidwell Park [email protected]
MONTEREY OCTOBER 12 Custom House Plaza, Monterey State Historic Park [email protected]
SAN JOSE OCTOBER 12 Arena Green [email protected]
STOCKTON OCTOBER 12 Victory Park [email protected]
PETALUMA OCTOBER 19 Shollenberger Park [email protected]
REDDING OCTOBER 19 Convention Center/Turtle Bay [email protected]
SUISUN CITY OCTOBER 26 Harbor Plaza [email protected]
9/7 9/28 10/12 10/19
ALZ.ORG/WALK | 800.272.3900
IN THIS ISSUE
Walk dates .................. Cover Think It Over .......................2 Alzheimer's Basics .............3 New Research Advances from AAIC .......4-5 Caregiver Corner: Complementary Therapies That May Help ....................6 On a Personal Note ............7 Action Items .......................7 Researchers Symposium ....8
Northern California and Northern Nevada Board Officers Geoff Heredia, President Howard Kirsch, Vice President Lucy Romoli, Vice President Joe Cooney, Treasurer
Pat Sippel, Secretary
Members Pat Baldridge Kerry de Benedetti Rob Fanno Chuck Haas Geoffrey Kerchner, MD, PhD Joan Kezic Michael Kirkland Renu Mahale Francie Newfield Denise Pringle Matthew Rhodes Jeffrey Teng Alex Tsao Leslie Walker William H. Fisher, CEO Ex officio Lennart Mucke, MD
Medical Scientific Advisory Council Lennart Mucke, MD, Chair Wes Ashford, MD, PhD Adam Boxer, MD, PhD Charles DeCarli, MD Dolores Gallagher-Thompson, PhD Michael Greicius, MD Victor Henderson, MD Ladson Hinton, MD William Jagust, MD Elizabeth Landsverk, MD Frank Longo, MD, PhD Michael McCloud, MD, FACP Jared Tinklenberg, MD Tony Wyss-Coray, PhD Kristine Yaffe, MD Elizabeth Edgerly, PhD, Chief
Northern Nevada Chapter Staff Jacob Harmon, Regional Director Vicki Lebsack, Program Director Dori Ward, Family Care Associate Erica Baker, Special Events Manager Nora Brennan, Founder2
It’s the “the Marching Season” – Walk to End Alzheimer’s – that time when we engage our communities to bring Alzheimer’s to the fore, to raise funds and awareness for our cause. Our communications team is hard at work trying to entice the media into paying attention, our public policy team is activating our advocates to influence policy makers, and all the while, we answer the phone and meet with families for whom concern and awareness and public policy are at best secondary issues.
We’re an Association of big dreams, but honestly, we didn’t start that way. We began just trying to make the journey a little easier for those who followed. As we worked, we learned that Alzheimer’s is not normal aging, not inevitable… we learned to hope. We learned that if we want to change the future, we need to organize, we need to engage, we need to lift our heads from the challenges of day-to-day caregiving.
Today we – you, me and millions we’ve never met – are a movement. We created the National Alzheimer’s Project Act, we moved its passage and now we have to make it matter. Our job in a very tangible way is to change the facts as we know them today… to quadruple Federal funding for Alzheimer’s research, to create better options of care, to reduce the stigma of Alzheimer’s, bringing it out of the closet and talking about it and diagnosing as the disease it is.
Walk to End Alzheimer’s is all about this. It is about moving concern and awareness, it is about linking people to help, engaging our families, neighbors and co-workers in a movement that reclaims the future for millions. It is about raising the essential dollars that stoke our work and allow us to expand our impact.
I love Walk for many reasons. I suspect part of it is being a child of the 60’s… seeing hundreds, even thousands of people out in the streets is, for me, cathartic. All those people, diverse strangers motivated by the same cause. Imagine if there were so many people turning out for Walk that we couldn’t hold the crowd, not enough parking, ran out of t-shirts. How big a crowd would it take for the media to cover the event? I don’t know, but I’d love to find out. If you care about this issue, for yourself, for your partner or spouse, for your
parents, for your children or grandchildren, you need to be there. Sign up, raise money, raise hell. Be the change we want to see. See you there.
Wm H. Fisher, [email protected]
Think It Over...
JOIN US LIKE US: facebook.com/AlzheimersCalifornia
WATCH US: youtube.com/AlzheimersNVCA
FOLLOW US: twitter.com/alznorcalnornev
ALZHEIMER’S BASICS: KNOW YOUR FACTS AND FIGURES! The Alzheimer’s Association annual Alzheimer’s Disease Facts and Figures report has been updated for 2013. Here are 10 Facts you’ll want to keep in your back pocket!
More than 5 million people in the U.S. have Alzheimer’s disease; by 2050, up to 16 million people will have the disease.
Alzheimer’s is the 6th leading cause of death in the U.S., killing more people each year than breast and prostate cancer combined.
One in every three seniors will either die with or from Alzheimer’s or another form of dementia.
Alzheimer’s is the only cause of death in the top 10 that cannot be prevented, cured or slowed.
Another American develops Alzheimer’s disease every 68 seconds; in 2050, an American will develop the disease every 33 seconds.
One in nine people over age 65 and one in three people over age 85 will get Alzheimer’s.
Deaths from Alzheimer’s increased 68 percent between 2000 and 2010, while deaths from other major diseases, including the number one cause of death (heart disease), decreased.
In 2013, the direct costs of caring for those with Alzheimer’s in the U.S. will total an estimated $203 billion.
In 2012, 15.4 million family and friends provided 17.5 billion hours of unpaid care to those with Alzheimer’s and other dementias – care valued at $216.4 billion.
Unless something is done, Alzheimer’s will cost an estimated $1.2 trillion (in today’s dollars) in 2050. Costs to Medicare and Medicaid will increase over 500 percent.
Did you know we have offices throughout Northern California and Northern Nevada? You can reach us by calling any time, day or night at 800.272.3900!
MOUNTAIN VIEW, CALIFORNIA 1060 La Avenida St.
CHICO, CALIFORNIA 2105 Forest Ave., Ste. 130
LAFAYETTE, CALIFORNIA 3675 Mt. Diablo Blvd., Ste. 250
MONTEREY, CALIFORNIA 21 Lower Ragsdale Dr., Ste. B
RENO, NEVADA 1301 Cordone Ave., Ste. 180
SACRAMENTO, CALIFORNIA 1455 Response Road, Ste. 190
SAN RAFAEL, CALIFORNIA 4340 Redwood Hwy., Ste. D314
SANTA CRUZ, CALIFORNIA 1777-A Capitola Road
SANTA ROSA, CALIFORNIA 1211 North Dutton Ave., Ste. A
The Alzheimer's Association International Conference (AAIC) is the premier event for presentations and discussion on the latest Alzheimer's and dementia research. AAIC 2013 brought together nearly 5,000 leading experts and researchers from around the world and featured more than 1,800 scientific presentations. Here are a few of the highlights:
FOR MORE INFORMATION ABOUT THESE AND OTHER STUDIES PRESENTED AT AAIC 2013, VISIT WWW.ALZ.ORG/AAIC.
ALZHEIMER’S DRUG STUDIES WITH INNOVATIVE APPROACHES Allopregnanolone, also known as Allo, is a neurosteroid found in the brain and bloodstream. In previous studies, it has shown promise as a potential regenerative therapy to promote brain cell creation and improve cognitive function in older animals and animal models of Alzheimer's disease. Allo is naturally expressed in the brain and reaches relatively high levels during the third trimester of pregnancy. Researchers reported the design of a Phase 1 clinical trial of Allo in participants diagnosed with MCI due to Alzheimer's and mild Alzheimer's.
Scientists are initiating an international Phase 3 trial of low dose pioglitazone, a medication which at higher doses is approved for treatment of type 2 diabetes, as a therapy to delay onset of MCI due to Alzheimer's.
New Research Advances from the Alzheimer's Association International Conference® 2013
A panel of experts reviewed 16 freely accessible online tests for Alzheimer's disease, and found that the tests scored poorly on scales of overall scientific validity, reliability and ethical factors.
Four studies supported increasing evidence that subjective cognitive decline (SCD) — the self-reported perception of memory or cognition proble